Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Medtronic’s Endeavor Resolute stent receives CE Mark

Medtronic : 23 October, 2007  (New Product)
Medtronic has received CE Mark approval for the commercial sale of the Endeavor Resolute Drug-Eluting Coronary Stent and will launch the product outside the USA earlier than originally projected.
The Endeavor Resolute Stent will be launched in more than 50 countries in Europe, Asia, the Middle East and Africa by the end of 2007 making Medtronic the first company to offer two internally developed drug-eluting Stent options for the treatment of coronary artery disease.

The new Stent is not approved in the USA. Endeavor Resolute adds an innovative new drug-eluting Stent to Medtronic’s international Stent portfolio, which also includes the Endeavor drug-eluting Stent and the Driver bare-metal stent. The expanded portfolio provides physicians with a greater variety of Stent choices to cover a wide range of patient needs.

Endeavor Resolute uses a proprietary new biocompatible polymer called BioLinx. The BioLinx polymer is designed to confer the same biocompatibility as the Endeavor stent’s phosphorylcholine (PC) polymer while extending the duration of drug exposure in the vessel.

Developed by Medtronic scientists, BioLinx is the first polymer created specifically for use on a drug-eluting stent. The BioLinx polymer features a unique blend of hydrophilic and hydrophobic elements for optimal performance. Extensive preclinical studies have established the biocompatibility and Drug delivery capabilities of the BioLinx polymer.

Prof Patrick W J C Serruys of the Heartcenter Rotterdam in The Netherlands performed the first commercial Implant of the Endeavor Resolute Stent on October 10, 2007.

“We now have a new drug-eluting Stent for our patients with a breakthrough in coating technology,” said Prof. Serruys. “This new BioLinx polymer has been fully assessed, both on biological and pharmacological parameters, and found to be compatible with blood, endothelial and smooth muscle cells.”

Prof Serruys added: “Endeavor Resolute provides the excellent safety profile of the Endeavor Stent with extended delivery of the drug zotarolimus. To further evaluate the safety and efficacy of the new Stent in real-world clinical practice, we have designed a post-market European study involving more than 2,300 patients.”

Patients treated with the Endeavor Resolute Stent in the initial Resolute clinical trial required no repeat procedures through nine months and had experienced no protocol-defined Stent thrombosis through 12 months of follow-up. In-stent late lumen loss at nine months, the study’s primary endpoint, was met at 0.22mm 0.27mm, providing assurance of vessel healing in the targeted range while preventing repeat procedures.

Among the trial’s 130 patients, only one required clinically driven Target Lesion Revascularization (TLR) or Target Vessel Revascularization (TVR) through 12 months. The incidence of major adverse cardiac events was 8.5 percent through 12 months. The 12 month results from the Resolute trial are available at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC, USA.

“The Resolute clinical results are impressive considering the enrolled patients presented with especially complex and challenging characteristics,” explained the trial’s principal investigator, Prof Ian Meredith of Monash Medical Centre in Melbourne, Australia.

These patients on average had longer lesions at 15.5mm, and 82 percent of the patients were classified as having very complex lesions.

“Endeavor Resolute continues to deliver impressive clinical outcomes,” said Prof Meredith. “The stent’s drug-and-polymer combination has successfully reduced restenosis in a particularly challenging patient group while maintaining an excellent safety profile.”

Medtronic plans additional clinical trials of the Endeavor Resolute Stent as part of a comprehensive programme to characterise the stent’s long term safety and efficacy in a variety of patient populations.

The programme will enroll approximately 13,000 patients in a series of randomised controlled trials and registries in the USA and internationally. Endeavor Resolute utilises the strengths of the Endeavor drug-eluting stent, which was launched in Europe in July 2005 and is now available in more than 100 countries outside the USA.

The stents share the same cobalt alloy Stent platform, which provides radial strength and conformability to the vessel wall, and both use the non-cytotoxic drug zotarolimus.

Both of Medtronic’s drug-eluting stents also use highly biocompatible polymers.

“The Endeavor Resolute drug-eluting Stent and the novel BioLinx polymer represent two important achievements of our robust product pipeline and demonstrate our commitment to innovation in interventional cardiology,” said Scott Ward, president of the CardioVascular business at Medtronic. “With the combination of Driver, Endeavor and Endeavor Resolute, Medtronic is delivering safe and effective options for physicians to treat a broad range of patients with coronary artery disease.”
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo